<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) has been reported after autologous bone marrow or peripheral blood stem cell transplantation (ABMT/PBSCT) for various <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We retrospectively reviewed <z:hpo ids='HP_0000001'>all</z:hpo> adult ABMT/PBSCT cases performed at the University of Chicago Medical Center from 1985 to 1997 in order to determine the incidence of therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Among 649 patients, seven (1.1%) developed therapy-related <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (one patient) or t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (six patients) </plain></SENT>
<SENT sid="3" pm="."><plain>Of these seven, primary <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> included one case of <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo>, five cases of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) and one case of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) </plain></SENT>
<SENT sid="4" pm="."><plain>Disease-specific incidences for therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> occurring after ABMT/PBSCT were one in 354 (0.3%) for <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo>, five in 79 (6.3%) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> and one in 103 (1%) for NHL </plain></SENT>
<SENT sid="5" pm="."><plain>The median latency periods for the development of therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> from the time of initial diagnosis and of ABMT/PBSCT were 5.5 and 1.5 years, respectively, for the combined <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> and NHL group of patients and 4.4 and 2.8 years, respectively, for the one <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> patient </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> seven patients had clonal cytogenetic abnormalities, and five had recurring abnormalities typical of myeloid disorders </plain></SENT>
<SENT sid="7" pm="."><plain>Given the similar latency period observed in patients treated with conventional chemotherapy alone, our findings support the hypothesis that therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> after ABMT/PBSCT likely results from pre-transplant therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Early detection of therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> is therefore critical to exclude these patients from undergoing ABMT/PBSCT </plain></SENT>
</text></document>